2018

Sanofi: FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine

Dengvaxia® vaccine approved for prevention of dengue in Europe

Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq

Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness

Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause

New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial

FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis

Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases

Sanofi Q3 2018 Performance Confirms Return to Growth

Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)

Sanofi receives positive CHMP opinion for dengue vaccine

Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

Sanofi completes divestiture of Zentiva to Advent

Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma

Sanofi: Availability of the Pre-quarterly Results Communication

Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab)

Sanofi to refocus two global business units

FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events

Sanofi reaches civil settlement with US SEC

Sanofi: Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

Online Availability of Sanofi Group's Half-Year Financial Report for 2018

Sanofi: Q2 2018 Performance Positions Sanofi for New Growth Phase

Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st

Sanofi: Availability of the Pre-quarterly Results Communication

Sanofi: CHMP recommends approval of Cablivi(TM) (caplacizumab)

Sanofi : Sanofi and Advent finalize negotiations for the acquisition of Zentiva

Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer

Sanofi : Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure

Sanofi : Sanofi successfully prices USD 2 billion bond issue

Sanofi Launches "Action 2018", a Worldwide Employee Stock Purchase Plan

Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma

Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma

Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period

Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period

Sanofi: Annual General Shareholders' Meeting of May 2, 2018

Sanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

Sanofi: First-quarter 2018 Business EPS(1) up 1.4% at CER

Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1

Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...

Sanofi to invest €350 million in Canadian vaccine facility

Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma

Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma

Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes

Previously announced Tender Offers by Sanofi to acquire Ablynx will commence on April 4, 2018

Sanofi: Availability of the Pre-quarterly Results Communication

Sanofi successfully prices EUR 8 billion of bond issues

Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need

Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate

Sanofi Completes Acquisition of Bioverativ Inc.

Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform

Sanofi: Filing of the 2017 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report

Sanofi's Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director

Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma

Sanofi Announces Receipt of Antitrust Clearances in Connection with the Acquisition of Ablynx

Sanofi: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Bioverativ

Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.

Sanofi Delivers 2017 Business EPS(1) in line with Guidance

Sanofi: Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment

CORRECTION:Sanofi va acquérir Ablynx pour 3,9 milliards d'euros

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi: Availability of the Pre-quarterly Results Communication

Sanofi to Acquire Bioverativ for $11.6 Billion

Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee

Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs

Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance